NO20072721L - Polypeptides that bind BR3 and uses thereof - Google Patents

Polypeptides that bind BR3 and uses thereof

Info

Publication number
NO20072721L
NO20072721L NO20072721A NO20072721A NO20072721L NO 20072721 L NO20072721 L NO 20072721L NO 20072721 A NO20072721 A NO 20072721A NO 20072721 A NO20072721 A NO 20072721A NO 20072721 L NO20072721 L NO 20072721L
Authority
NO
Norway
Prior art keywords
polypeptides
methods
bind
relates
present
Prior art date
Application number
NO20072721A
Other languages
English (en)
Inventor
Henry B Lowman
Christine M Ambrose
Jeffrey S Thompson
Gerald R Nakamura
Flavius Martin
Germaine Fuh
Mark S Dennis
Mercedesz Balazs
Laura Deforge
Stephen D Hurst
Chingwei V Lee
Dhaya Seshasayee
Melissa Starovasnik
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20072721L publication Critical patent/NO20072721L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)

Abstract

Den foreliggende oppfinnelsen angår nye BR3-bindende antistoffer og polypeptider inklusive antagonist- og agonistpolypeptider. Den foreliggende oppfinnelsen angår også anvendelsen av de BR3-bindende antistoffene og polypeptidene, for eksempel i behandlingsmetoder, screeningsmetoder, diagnostiske metoder, prøver og proteinrensemetoder.
NO20072721A 2004-12-31 2007-05-29 Polypeptides that bind BR3 and uses thereof NO20072721L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64032304P 2004-12-31 2004-12-31
PCT/US2005/047072 WO2006073941A2 (en) 2004-12-31 2005-12-23 Polypeptides that bind br3 and uses thereof

Publications (1)

Publication Number Publication Date
NO20072721L true NO20072721L (no) 2007-10-01

Family

ID=36588679

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072721A NO20072721L (no) 2004-12-31 2007-05-29 Polypeptides that bind BR3 and uses thereof

Country Status (14)

Country Link
US (2) US20080181888A1 (no)
EP (1) EP1838735A2 (no)
JP (1) JP2008526205A (no)
KR (1) KR20070107687A (no)
CN (1) CN101120021A (no)
AP (1) AP2007004034A0 (no)
AU (1) AU2005323025A1 (no)
BR (1) BRPI0518994A2 (no)
CA (1) CA2595112A1 (no)
EA (1) EA200701211A1 (no)
IL (1) IL183353A0 (no)
MX (1) MX2007008017A (no)
NO (1) NO20072721L (no)
WO (1) WO2006073941A2 (no)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
US20110129414A1 (en) * 2005-11-15 2011-06-02 Balyasnikova Irina V Single Chain Fragment of Monoclonal Antibody 9B9 and Uses Thereof
US7807794B2 (en) * 2005-11-18 2010-10-05 Glenmark Pharmaceuticals S.A. Anti-α2 integrin antibodies and their uses
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック, インコーポレイテッド B細胞アッセイに関する組成物及び方法。
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
WO2008008482A2 (en) * 2006-07-13 2008-01-17 Genentech, Inc. Altered br3-binding polypeptides
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
WO2008098145A1 (en) * 2007-02-07 2008-08-14 University Of Washington Methods for modulating antigen-specific b cell responses
KR20090114443A (ko) * 2007-02-09 2009-11-03 제넨테크, 인크. 항-Robo4 항체 및 그의 용도
WO2009012268A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
TW200918089A (en) 2007-07-16 2009-05-01 Genentech Inc Humanized anti-CD79b antibodies and immunoconjugates and methods of use
CA2712303C (en) 2008-01-18 2015-03-31 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
ES2587392T3 (es) 2008-01-31 2016-10-24 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
SI2315780T1 (sl) 2008-07-17 2015-11-30 Novartis Ag Sestavki in postopki uporabe za terapevtska protitelesa
CN102245208B (zh) 2008-10-14 2016-03-16 霍夫曼-拉罗奇有限公司 免疫球蛋白变体及其用途
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
PT4209510T (pt) * 2008-12-09 2024-04-02 Hoffmann La Roche Anticorpos anti-pm-l1 e a sua utilização para a melhoria do funcionamento das células t
MX2011006870A (es) 2008-12-23 2011-07-19 Genentech Inc Variantes de inmunoglobulina con union alterada a proteina a.
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
CA2772670A1 (en) 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
AU2010300747A1 (en) 2009-09-30 2012-04-26 Genentech, Inc. Treating Notch1-antagonist-resistant cancer (s) using Notch3 antagonists
ES2565208T3 (es) 2009-12-11 2016-04-01 F. Hoffmann-La Roche Ag Anticuerpos anti-VEGF-C y métodos de uso de los mismos
WO2011088111A1 (en) * 2010-01-12 2011-07-21 Genentech, Inc. ANTI-PlGF ANTIBODIES AND METHODS USING SAME
AR080301A1 (es) 2010-02-24 2012-03-28 Immunogen Inc Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
CN101851278B (zh) * 2010-05-26 2013-03-13 石药集团中奇制药技术(石家庄)有限公司 B细胞激活因子拮抗剂及其制备方法与用途
MX2013000917A (es) 2010-07-23 2013-07-05 Harvard College Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
EP2596116A4 (en) 2010-07-23 2014-03-19 Harvard College METHODS FOR DETECTION OF AUTOIMMUNE OR IMMUNE-RELATED DISEASES / PATHOLOGIES
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
BR112013001754A2 (pt) 2010-07-23 2016-05-31 Harvard College método para detectar marcas de doença ou condições em fluídos corpóreos
AU2011281007A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting kidney-associated diseases or conditions
AU2011295902B2 (en) 2010-09-02 2014-12-04 Vaccinex, Inc. Anti-CXCL13 antibodies and methods of using the same
EP2648750B1 (en) * 2010-12-10 2017-01-25 Novartis AG Antibody formulation
EA037071B1 (ru) 2011-01-14 2021-02-02 Юсб Байофарма Срл Молекулы антител, которые связываются с il-17a и il-17f
RS56916B1 (sr) 2011-04-01 2018-05-31 Immunogen Inc Postupci za povećanje efikasnosti terapije kancera usmerene na folr1
EP2700653B1 (en) * 2011-04-15 2019-07-24 SNU R&DB Foundation Complex in which anti-cotinine antibody is bound to conjugate of cotinine and binding substance, and use therefor
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CA2849011A1 (en) 2011-10-05 2013-04-11 Genentech, Inc. Methods of treating liver conditions using notch2 antagonists
WO2013130959A1 (en) 2012-03-02 2013-09-06 Vaccinex, Inc. Methods for the treatment of b cell-mediated inflammatory diseases
US10481164B2 (en) * 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
EP2831115A1 (en) 2012-03-27 2015-02-04 F. Hoffmann-La Roche AG Diagnosis and treatments relating to her3 inhibitors
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
EP2890717B1 (en) 2012-08-31 2020-03-04 ImmunoGen, Inc. Diagnostic assays and kits for detection of folate receptor 1
EP2920300B1 (en) * 2012-11-13 2018-09-12 F.Hoffmann-La Roche Ag Enrichment of antigen-specific plasmablasts
EP2951204B1 (en) 2013-01-31 2019-05-22 Vaccinex, Inc. Methods for increasing immunoglobulin a levels
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
US10494675B2 (en) 2013-03-09 2019-12-03 Cell Mdx, Llc Methods of detecting cancer
MX2015010854A (es) 2013-03-14 2016-07-20 Genentech Inc Combinaciones de un compuesto inhibidor de mek con un compuesto inhibidor de her3/egfr y metodos de uso.
US20160053023A1 (en) 2013-04-09 2016-02-25 Annexon, Inc. Methods of treatment for neuromyelitis optica
MX2015017341A (es) 2013-07-09 2016-07-06 Anexxon Inc Anticuerpos anti-factor del complemento c1q y uso de los mismos.
UA120166C2 (uk) 2013-08-30 2019-10-25 Іммуноджен, Інк. Антитіло, що специфічно зв'язується з folr1, та спосіб виявлення рецептора фолієвої кислоти 1
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
CA3090240A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
HUE049175T2 (hu) 2014-09-23 2020-09-28 Hoffmann La Roche Eljárás anti-CD79b immunkonjugátumok alkalmazására
EP3215527A4 (en) 2014-11-05 2018-04-18 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof
EP3991748A3 (en) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
WO2016179101A2 (en) 2015-05-01 2016-11-10 Inhibrx Lp Type iii secretion system targeting molecules
JP7376977B2 (ja) 2015-06-12 2023-11-09 アレクトル エルエルシー 抗cd33抗体及びその使用方法
US11174313B2 (en) 2015-06-12 2021-11-16 Alector Llc Anti-CD33 antibodies and methods of use thereof
CN107922491B (zh) 2015-07-16 2021-09-28 印希比股份有限公司 多价和多特异性结合dr5的融合蛋白
JP7525980B2 (ja) 2015-08-28 2024-07-31 アレクトル エルエルシー 抗Siglec-7抗体及びその使用方法
MA42844A (fr) 2015-09-17 2018-07-25 Immunogen Inc Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1
JP2018537956A (ja) 2015-10-06 2018-12-27 アレクトル エルエルシー 抗trem2抗体及びその使用方法
KR20180084817A (ko) 2015-10-29 2018-07-25 알렉터 엘엘씨 항-siglec-9 항체 및 이의 이용 방법
US11472877B2 (en) 2016-03-04 2022-10-18 Alector Llc Anti-TREM1 antibodies and methods of use thereof
JP7275446B2 (ja) 2016-06-06 2023-05-18 シティ・オブ・ホープ Baff-r抗体及びその使用
SG11201810887UA (en) * 2016-06-06 2019-01-30 Hope City Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
BR112019012964A2 (pt) * 2016-12-22 2019-10-08 Cue Biopharma Inc polipeptídeos multiméricos moduladores de célula t e métodos de uso dos mesmos
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
PE20200486A1 (es) 2017-08-03 2020-03-03 Alector Llc Anticuerpos anti-cd33 y metodos para utilizarlos
MD3601358T2 (ro) 2017-08-03 2023-10-31 Alector Llc Anticorpi anti-TREM2 și metode de utilizare a acestora
EP3456738B1 (en) 2017-09-19 2024-07-17 Tillotts Pharma Ag Antibody variants
EP3456737B1 (en) 2017-09-19 2024-02-14 Tillotts Pharma Ag Antibody variants
EP3456739A1 (en) 2017-09-19 2019-03-20 Tillotts Pharma Ag Use of anti-tnfalpha antibodies for treating wounds
PT3456736T (pt) 2017-09-19 2021-05-28 Tillotts Pharma Ag Variantes de anticorpos
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
WO2019084553A1 (en) 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
AR115418A1 (es) 2018-05-25 2021-01-13 Alector Llc ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS
AU2019282778A1 (en) 2018-06-08 2020-12-10 Alector Llc Anti-Siglec-7 antibodies and methods of use thereof
SI3618928T1 (sl) 2018-07-13 2023-04-28 Alector Llc Protitelesa proti sortilinu in postopki za uporabo le-teh
CA3118453A1 (en) 2018-11-02 2020-05-07 The Regents Of The University Of California Compositions and methods for treating brain injury
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
WO2020154889A1 (zh) * 2019-01-29 2020-08-06 上海鑫湾生物科技有限公司 具有Fc突变体的抗体与效应细胞的组合、用途和制法
SG11202112112UA (en) * 2019-05-01 2021-11-29 Univ New York Anti-galectin-9 antibodies and uses thereof
US12023354B2 (en) 2019-05-31 2024-07-02 Case Western Reserve University Targeting B cell activating factor receptor (BAFF-R) using ligand-based chimeric antigen receptor (CAR)-T cells
EP3986937A1 (en) 2019-12-05 2022-04-27 Alector LLC Methods of use of anti-trem2 antibodies
BR112022011337A2 (pt) 2019-12-12 2022-08-23 Alector Llc Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo
US20230159637A1 (en) 2020-02-24 2023-05-25 Alector Llc Methods of use of anti-trem2 antibodies
CN115867649A (zh) 2020-03-24 2023-03-28 基因泰克公司 Tie2结合剂及其使用方法
CA3172451A1 (en) 2020-04-03 2021-10-07 Robert Paul Methods of use of anti-trem2 antibodies
WO2021226553A2 (en) * 2020-05-08 2021-11-11 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
CN112999346A (zh) * 2021-03-04 2021-06-22 华中科技大学同济医学院附属协和医院 Baff抗体在制备治疗炎症性肠病药物中的应用
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
WO2023164516A1 (en) 2022-02-23 2023-08-31 Alector Llc Methods of use of anti-trem2 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
NZ539776A (en) * 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
JP2005510208A (ja) * 2001-08-03 2005-04-21 ジェネンテック・インコーポレーテッド TACIs及びBR3ポリペプチドとその用途
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization

Also Published As

Publication number Publication date
EA200701211A1 (ru) 2007-12-28
JP2008526205A (ja) 2008-07-24
CN101120021A (zh) 2008-02-06
WO2006073941A3 (en) 2006-08-31
MX2007008017A (es) 2007-09-12
US20100280227A1 (en) 2010-11-04
WO2006073941A9 (en) 2007-07-05
AP2007004034A0 (en) 2007-06-30
EP1838735A2 (en) 2007-10-03
CA2595112A1 (en) 2006-07-13
BRPI0518994A2 (pt) 2008-12-02
WO2006073941A2 (en) 2006-07-13
IL183353A0 (en) 2008-04-13
KR20070107687A (ko) 2007-11-07
AU2005323025A1 (en) 2006-07-13
US20080181888A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
NO20072721L (no) Polypeptides that bind BR3 and uses thereof
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
BRPI0520677A2 (pt) identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
CY1117702T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ικανες να δεσμευονται με θυμικη στρωματικη λεμφοποιητινη
HUP0202532A2 (hu) Ko-stimulátor szignál-transzdukciós molekula (AILIM) elleni humán monoklonális antitest és gyógyászati alkalmazása
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
EP2298813A3 (en) Anti-TRKB monoclonal antibodies and uses thereof
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
MA35208B1 (fr) Protéines de liaison à bcma (cd269/tnfrsf17)
MX2009012949A (es) Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos.
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
UA109633C2 (uk) Антитіло людини проти тканинного фактора
UA96139C2 (uk) Антитіло до нейропіліну-1 (nrp1)
TW200626614A (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
BR112014010161A2 (pt) anticorpo monoclonal antiproteína de ligação ao dna tar de 43 kda (tdp-43) e seus método de preparação e uso no tratamento de proteinopatia tdp-43, bem como composições, polinucleotídeo, método in vitro e kit para diagnosticar proteinopatia tdp-43
DE602006013029D1 (de) Anti-egfr-antikörper
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
MX2008009886A (es) Anticuerpos que enlazan par-2.
ATE505489T1 (de) Tgf-beta-1-spezifische antikörper
CL2011000010A1 (es) Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende.
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application